Raadi | Blue Cross MN

Soo bandhiga 2231 - 2240 ee natiijooyinka 3613

Bixiye

P17-20 Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Subscribers – eviCore Healthcare Specialty Utilization Management (UM) Program

Wax badan akhri

Taariikhda uu dhaqangalayo Barnaamijka: Mar 02, 2020

Bixiye

QP23-20 Blue Cross Basic Seminar Now Available On-Demand through the Availity Portal

Wax badan akhri

Taariikhda uu dhaqangalayo Barnaamijka: 26, Feb 2020

Bixiye

QP17-20 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Wakix ®

Wax badan akhri

Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020

Bixiye

QP14R1-20 Update: New Service Type Options for Inpatient Admission Notifications on Availity Portal

Wax badan akhri

Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020

Bixiye

QP19-20 Provider Overpayments and Overpayment Recoupment for MHCP

Wax badan akhri

Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020

Bixiye

QP22-20 Pharmacy Benefit Exclusion for Tepezza TM

Wax badan akhri

Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020

Bixiye

QP16-20 Pharmacy Benefit Exclusion for Padcev TM and Enhertu ®

Wax badan akhri

Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020

Bixiye

QP21-20 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Baclofen

Wax badan akhri

Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020

Bixiye

QP18-20 Pharmacy Benefit Exclusion for Calcipotriene-Betamethasone Dipropionate Suspension 0.005-0.064% (authorized generic (AG) of Taclonex suspension)

Wax badan akhri

Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020

Bixiye

P9-20 MHCP Prenatal Service Third Party Liability Change

Wax badan akhri

Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020